2020 年亚太心脏病学会关于亚太地区使用 P2Y12 受体拮抗剂的共识建议

2021-07-01 亚太心脏病协会APSC Eur Cardiol . 2021 Mar 2;16:e02. doi: 10.15420/ecr.2020.40

亚太地区急性冠脉综合征患者的独特特征意味着双重抗血小板治疗(DAPT)的国际指南不能常规应用于这些人群。与氯吡格雷相比,新一代 P2Y12 抑制剂(即替格瑞洛和普拉格雷)的临床结果有所改善。然而,参与

中文标题:

2020 年亚太心脏病学会关于亚太地区使用 P2Y12 受体拮抗剂的共识建议

发布机构:

亚太心脏病协会APSC

发布日期:

2021-07-01

简要介绍:

亚太地区急性冠脉综合征患者的独特特征意味着双重抗血小板治疗(DAPT)的国际指南不能常规应用于这些人群。与氯吡格雷相比,新一代 P2Y12 抑制剂(即替格瑞洛和普拉格雷)的临床结果有所改善。然而,参与关键研究的亚洲患者数量很少,并且很少进行比较 DAPT 的区域研究。本文旨在总结在亚洲急性冠脉综合征患者中使用新一代 P2Y12 抑制剂的当前证据,并提供建议以帮助临床医生,尤其是心脏病专家,选择 DAPT 方案。提供了有关缺血和出血风险管理的指南,包括治疗持续时间、转换策略以及 ST 段抬高和非 ST 段抬高 MI 或需要手术的患者的管理。特别讨论了个体化 DAPT 方案的必要性以及与转换、降级、停止或继续 DAPT 超过 12 个月相关的注意事项。

相关资料下载:
[AttachmentFileName(sort=1, fileName=66.pdf)] GetToolGuiderByIdResponse(projectId=1, id=c77e01c002132218, title=2020 年亚太心脏病学会关于亚太地区使用 P2Y12 受体拮抗剂的共识建议 , enTitle=, guiderFrom=Eur Cardiol . 2021 Mar 2;16:e02. doi: 10.15420/ecr.2020.40, authorId=0, author=, summary=亚太地区急性冠脉综合征患者的独特特征意味着双重抗血小板治疗(DAPT)的国际指南不能常规应用于这些人群。与氯吡格雷相比,新一代 P2Y12 抑制剂(即替格瑞洛和普拉格雷)的临床结果有所改善。然而,参与, cover=, journalId=0, articlesId=null, associationId=1944, associationName=亚太心脏病协会APSC, associationIntro=Asian Pacific Society of Cardiology (APSC), copyright=0, guiderPublishedTime=Thu Jul 01 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span class="VIiyi" lang="zh-CN"><span class="JLqJ4b" data-language-for-alternatives="zh-CN" data-language-to-translate-into="en" data-phrase-index="0">亚太地区急性冠脉综合征患者的独特特征意味着双重抗血小板治疗(DAPT)的国际指南不能常规应用于这些人群。与氯吡格雷相比,新一代 P2Y12 抑制剂(即替格瑞洛和普拉格雷)的临床结果有所改善。然而,参与关键研究的亚洲患者数量很少,并且很少进行比较 DAPT 的区域研究。本文旨在总结在亚洲急性冠脉综合征患者中使用新一代 P2Y12 抑制剂的当前证据,并提供建议以帮助临床医生,尤其是心脏病专家,选择 DAPT 方案。提供了有关缺血和出血风险管理的指南,包括治疗持续时间、转换策略以及 ST 段抬高和非 ST 段抬高 MI 或需要手术的患者的管理。特别讨论了个体化 DAPT 方案的必要性以及与转换、降级、停止或继续 DAPT 超过 12 个月相关的注意事项。</span></span></p>, tagList=[TagDto(tagId=360, tagName=急性冠脉综合征)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=43, categoryName=冠心病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=11537, appHits=50, showAppHits=0, pcHits=578, showPcHits=11487, likes=0, shares=11, comments=7, approvalStatus=1, publishedTime=Fri Jul 16 20:54:50 CST 2021, publishedTimeString=2021-07-01, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=fbzhang, createdTime=Fri Jul 16 20:54:06 CST 2021, updatedBy=4754896, updatedName=fbzhang, updatedTime=Tue Jan 02 22:30:21 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=66.pdf)])
66.pdf
下载请点击:
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1080579, encodeId=fa5e10805e90b, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:07:08 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080544, encodeId=e49b10805448c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 08:41:47 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064779, encodeId=3e2f1064e794f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=116a5651959, createdName=ms3000000802209056, createdTime=Thu Oct 28 20:31:48 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057489, encodeId=f07f105e489bd, content=不错 谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Mon Oct 04 14:00:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007417, encodeId=0dd2100e417fd, content=对亚太人群治疗很有意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210812/3490cc7ee4a2417bae03314d2ca28bfe/87a1295534564643a59f57691bc7304f.jpg, createdBy=8ebd2201249, createdName=鲁咏, createdTime=Thu Aug 12 21:47:12 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
    2021-12-16 龙珠

    好资料

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1080579, encodeId=fa5e10805e90b, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:07:08 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080544, encodeId=e49b10805448c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 08:41:47 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064779, encodeId=3e2f1064e794f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=116a5651959, createdName=ms3000000802209056, createdTime=Thu Oct 28 20:31:48 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057489, encodeId=f07f105e489bd, content=不错 谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Mon Oct 04 14:00:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007417, encodeId=0dd2100e417fd, content=对亚太人群治疗很有意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210812/3490cc7ee4a2417bae03314d2ca28bfe/87a1295534564643a59f57691bc7304f.jpg, createdBy=8ebd2201249, createdName=鲁咏, createdTime=Thu Aug 12 21:47:12 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
    2021-12-16 龙珠

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1080579, encodeId=fa5e10805e90b, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:07:08 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080544, encodeId=e49b10805448c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 08:41:47 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064779, encodeId=3e2f1064e794f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=116a5651959, createdName=ms3000000802209056, createdTime=Thu Oct 28 20:31:48 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057489, encodeId=f07f105e489bd, content=不错 谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Mon Oct 04 14:00:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007417, encodeId=0dd2100e417fd, content=对亚太人群治疗很有意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210812/3490cc7ee4a2417bae03314d2ca28bfe/87a1295534564643a59f57691bc7304f.jpg, createdBy=8ebd2201249, createdName=鲁咏, createdTime=Thu Aug 12 21:47:12 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
    2021-10-28 ms3000000802209056

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1080579, encodeId=fa5e10805e90b, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:07:08 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080544, encodeId=e49b10805448c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 08:41:47 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064779, encodeId=3e2f1064e794f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=116a5651959, createdName=ms3000000802209056, createdTime=Thu Oct 28 20:31:48 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057489, encodeId=f07f105e489bd, content=不错 谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Mon Oct 04 14:00:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007417, encodeId=0dd2100e417fd, content=对亚太人群治疗很有意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210812/3490cc7ee4a2417bae03314d2ca28bfe/87a1295534564643a59f57691bc7304f.jpg, createdBy=8ebd2201249, createdName=鲁咏, createdTime=Thu Aug 12 21:47:12 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
    2021-10-04 H8888888

    不错 谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1080579, encodeId=fa5e10805e90b, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:07:08 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080544, encodeId=e49b10805448c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 08:41:47 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064779, encodeId=3e2f1064e794f, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=116a5651959, createdName=ms3000000802209056, createdTime=Thu Oct 28 20:31:48 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057489, encodeId=f07f105e489bd, content=不错 谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Mon Oct 04 14:00:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007417, encodeId=0dd2100e417fd, content=对亚太人群治疗很有意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210812/3490cc7ee4a2417bae03314d2ca28bfe/87a1295534564643a59f57691bc7304f.jpg, createdBy=8ebd2201249, createdName=鲁咏, createdTime=Thu Aug 12 21:47:12 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
    2021-08-12 鲁咏

    对亚太人群治疗很有意义

    0